Chong Kun Dang issues unguaranteed bonds to secure clinical expenses.
Chong Kun Dang announced on the 9th that it would issue 100 billion won worth of bearer-type, non-guaranteed bonds with interest.
| ▲ Kim Young-joo, President and CEO of Chong Kun Dang. |
The total electronic registration of bonds is 80 billion won with a three-year maturity and 20 billion won with a five-year maturity. The interest rates are 1.995% and 2.287%, respectively.
The acquisition targets include NH Investment & Securities (40 billion won), Korea Investment & Securities (40 billion won), and Samsung Securities (20 billion won).
The funds secured by the issuance of non-guaranteed bonds are used for clinical trial expenses.
Chong Kun Dang is currently conducting phase 3 clinical trials for ‘Napabeltan’, a candidate for the treatment of COVID-19, and phase 1/2 clinical trials for ‘CKD-702’, a dual anticancer antibody candidate. [비즈니스포스트 조윤호 기자]
.
